CHA Health Systems Inc., a S. Korea-based global healthcare enterprise, has inked an MoU with Japanese medical corporation Otsubo-Kai to conduct joint researches on regenerative medicine, including stem cells and immune cells, thus laying the groundwork for Korea-Japan joint researches on cell therapies.
The signing of the MoU between the two healthcare heavyweights is expected to give an impetus to Tokyo Cell Clinic (TCC), CHA Health Systems’ Japanese unit. Following numerous trips back and forth between S. Korea and Japan, CHA Health Systems and Otsubokai have agreed to carry out joint research across the spectrum of regenerative medicine, including stem cells. On top of that, the MoU will pave the way for the export of CHA Health Systems’ infertility treatment to the Japanese market.
Both also have reached a preliminary agreement to accept each nation’s medical checkups and health examination systems, exchange excellent biotechnology personnel, resident physicians, professors and to hold Korea-Japan medical seminars and symposiums.
“I was inspired by CHA Health Systems’ progress in regenerative medicine research and infertility treatment and by its novel hospital model ‘Chaum.’ I believe that our tie-up with CHA Health Systems would breathe new life into the Japanese healthcare industry,” said Osamu Otsubo, chairman of Otsubokai’s board of directors.
“Otsubokai put a high premium on the advanced systems of CHA Health Systems’ Chaum, a premier wellness, longevity, and aesthetic medical facility located in Seoul, and CHA Bio Complex, located in Bundang. As Otsubokai is an influential medical group in Japan, we can create a lot of synergies by closely cooperating with Otsubokai,” said an official from CHA Health Systems.
Meanwhile, Tokyo Cell Clinic (TCC), founded last year, is thought to have successfully penetrated the Japanese market, backed by its cutting-edge medical services related to cell therapy, anti-aging treatment and genomes. Tokyo Cell Clinic specializes in immunotherapy and anti-aging treatment, which are considered as the most state-of-the-art medical fields in Japan. To that end, Tokyo Cell Clinic has been running a cutting-edge in-house cell processing center (CPC) that lives up to the international standards for medical treatment.
By Lee Jae-seung